Steve Chesney
Stock Analyst at Redburn Atlantic
(2.12)
# 1,461
Out of 4,479 analysts
41
Total ratings
58.06%
Success rate
-0.1%
Average return
Main Sectors:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $545 | $473.78 | +15.03% | 1 | Jun 27, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $77 → $54 | $40.45 | +33.50% | 7 | Feb 6, 2024 | |
| BIIB Biogen | Maintains: Neutral | $282 → $275 | $228.82 | +20.18% | 5 | Aug 8, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $167 → $170 | $146.03 | +16.41% | 6 | Aug 4, 2023 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $600 | $477.23 | +25.73% | 7 | Aug 2, 2023 | |
| ZTS Zoetis | Reiterates: Overweight | $225 | $174.81 | +28.71% | 2 | Jun 14, 2023 | |
| MRK Merck & Co. | Maintains: Overweight | $127 → $129 | $127.72 | +1.00% | 5 | May 1, 2023 | |
| ABBV AbbVie | Maintains: Neutral | $157 → $154 | $165.96 | -7.21% | 4 | Feb 10, 2023 | |
| PFE Pfizer | Maintains: Neutral | $50 → $46 | $27.83 | +65.29% | 2 | Feb 1, 2023 | |
| AMGN Amgen | Maintains: Underweight | $190 → $182 | $310.77 | -41.44% | 2 | Aug 9, 2022 |
Vertex Pharmaceuticals
Jun 27, 2024
Initiates: Buy
Price Target: $545
Current: $473.78
Upside: +15.03%
Bristol-Myers Squibb Company
Feb 6, 2024
Downgrades: Neutral
Price Target: $77 → $54
Current: $40.45
Upside: +33.50%
Biogen
Aug 8, 2023
Maintains: Neutral
Price Target: $282 → $275
Current: $228.82
Upside: +20.18%
Johnson & Johnson
Aug 4, 2023
Maintains: Neutral
Price Target: $167 → $170
Current: $146.03
Upside: +16.41%
IDEXX Laboratories
Aug 2, 2023
Downgrades: Neutral
Price Target: $600
Current: $477.23
Upside: +25.73%
Zoetis
Jun 14, 2023
Reiterates: Overweight
Price Target: $225
Current: $174.81
Upside: +28.71%
Merck & Co.
May 1, 2023
Maintains: Overweight
Price Target: $127 → $129
Current: $127.72
Upside: +1.00%
AbbVie
Feb 10, 2023
Maintains: Neutral
Price Target: $157 → $154
Current: $165.96
Upside: -7.21%
Pfizer
Feb 1, 2023
Maintains: Neutral
Price Target: $50 → $46
Current: $27.83
Upside: +65.29%
Amgen
Aug 9, 2022
Maintains: Underweight
Price Target: $190 → $182
Current: $310.77
Upside: -41.44%